Who is sponsoring NCT05827198?

NCT05827198 is sponsored by Mondelēz International, Inc..

What drugs are being tested in NCT05827198?

Interventions in NCT05827198: Low-sugar candies compared to regular sugar candies.

What condition does NCT05827198 study?

NCT05827198 studies Gastrointestinal Tolerance, Healthy Population.

Is NCT05827198 still recruiting?

NCT05827198 is currently status unknown. Last updated 8 September 2023.

Last reviewed 2023-09-08 · How we verify

NCT05827198

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating the Impact of Incremental Doses of a Sugar Replacer Blend on Gastrointestinal Tolerance in Candies

Status unknown NA Last updated 8 September 2023

What this trial tests

NA trial testing Low-sugar candies compared to regular sugar candies in Gastrointestinal Tolerance in 60 participants. Status unknown.

Timeline

12 September 2023

Primary endpoint
22 December 2023

27 January 2024

Quick facts

Lead sponsor	Mondelēz International, Inc.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	prevention
Enrollment	60
Start date	12 September 2023
Primary completion	22 December 2023
Estimated completion	27 January 2024
Sites	1 location across Canada

Drugs / interventions tested

Low-sugar candies compared to regular sugar candies

Conditions studied

Gastrointestinal Tolerance — all drugs for Gastrointestinal Tolerance →
Healthy Population — all drugs for Healthy Population →

Sponsor

Mondelēz International, Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Gastrointestinal Tolerance or Healthy Population. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a randomized, single-blind, crossover trial aiming at evaluating the gastrointestinal tolerance of a sugar replacer blend (inulin + soluble corn fiber + erythritol) at 3 different doses

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Mondelēz International, Inc. trials

Trials by the same sponsor.

NCT07372482 — Evaluating the Impact of Fat and Sugar Replacer Blends on Gastrointestinal Tolerance in Biscuits · NA · completed
NCT06479330 — Evaluating the Impact of Incremental Doses of a Sugar Replacer Blend on Gastrointestinal Tolerance in Chocolate · NA · completed
NCT05794100 — Evaluating the Impact of Different Sugar Replacer Combinations on Gastrointestinal Tolerance · NA · completed
NCT03847701 — Cardio-metabolic and Inflammatory Impact of Starch Digestibility in Type 2 Diabetic Patients · NA · completed
NCT03289494 — Evaluation of 2 Diets With Different Starch Digestibility Profiles on Daily Glycemic Profile, in T2D Patients · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05827198 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mondelēz International, Inc.
Last refreshed: 8 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05827198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing